Neurology
MOGAD May Finally Have a Clue to Who Relapses
An international study links antibodies against the MOGα3 isoform with a substantially higher relapse risk. The biomarker is not ready to dictate treatment, but it could eventually help answer one of MOGAD’s hardest questions.
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
Prevention Is Now Alzheimer’s Hardest Trial
Microglia Are Not a Shortcut to Alzheimer’s Certainty
Migraine Still Refuses a Simple Blood Test
A Blood Test Can See Risk. Policy Cannot Yet Hold It.
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
Cataplexy Is Waiting on an FDA Clock
Tau Is Back. Certainty Is Not.
Alzheimer’s Treatment Moves Home. Risk Does Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Neurology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases